OrbiMed’s QIAGEN NV QGENF Stock Holding History

OrbiMed’s Portfolio QGENF Stock Details QGENF Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-256,800	Closed	-$5.74M	–	156
2016 Q1	$5.74M	Buy	+256,800	New	+$5.74M	0.06%	112
2014 Q4	–	Sell	-1,700,000	Closed	-$38.7M	–	147
2014 Q3	$38.7M	Buy	1,700,000 +918,600	+118%	+$20.9M	0.4%	51
2014 Q2	$19.1M	Buy	+781,400	New	+$19.1M	0.22%	64
2014 Q1	–	Sell	-1,927,000	Closed	-$45.9M	–	153
2013 Q4	$45.9M	Buy	+1,927,000	New	+$45.9M	0.67%	44

Other funds holding QGENF

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

MNA

Manning & Napier Advisors Fairport, New York $7.09B AUM 17.35% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

CRM

Cramer Rosenthal McGlynn Stamford, Connecticut $1.36B AUM 31.72% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

HJGA

Hardman Johnston Global Advisors Stamford, Connecticut $2.1B AUM 41.89% 1-Year Est. Return

OrbiMed's QGENF Position: Q2 2016 in Review

OrbiMed sold out of QIAGEN NV (QGENF) in Q2 2016, closing a stake of 256,800 shares — an estimated $5.74M sold.

OrbiMed first reported a position in QGENF in Q4 2013 and held it in 4 quarters. The position peaked at $45.9M in Q4 2013. 188 funds tracked by Wall St. Rank hold QGENF as of Q2 2016.

OrbiMed reported no remaining QIAGEN NV position as of Q2 2016 after selling out during the quarter.
OrbiMed sold 256,800 QIAGEN NV shares in Q2 2016, an estimated $5.74M.
OrbiMed first reported a position in QIAGEN NV in Q4 2013 and held it in 4 quarters.
OrbiMed's QIAGEN NV position peaked at $45.9M in Q4 2013.
188 funds tracked by Wall St. Rank held QIAGEN NV as of Q2 2016.

Based on OrbiMed's 13F filing for Q2 2016, filed 15 Aug 2016.